Skip to main content
CB

Cape Bio Pharms

Cape Bio Pharms produces recombinant proteins using Nicotiana benthamiana plants, which enhances yield and lowers production costs compared to conventional methods. This technology provides a scalable solution for efficient protein production in biopharmaceutical applications.

Cape Town, South AfricaFounded 2018
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional methods of producing recombinant proteins for research and diagnostic applications often face challenges related to scalability, high production costs, and reliance on animal products. These limitations can hinder the accessibility and affordability of crucial proteins needed for advancing scientific research and improving global biosecurity.

Solution

Cape Biologix Technologies addresses these challenges by utilizing a plant-based expression platform, PtX™ Technology, that transforms Nicotiana benthamiana plants into miniature bioreactors for recombinant protein production. This transient expression system offers a compelling alternative to conventional methods, providing superior speed, flexibility, and scalability while eliminating the use of animal products. The plant-based approach enables the ethical and efficient manufacturing of high-quality proteins, contributing to improved health and well-being for both humans and animals. Cape Biologix Technologies aims to enhance global biosecurity by making these plant-made proteins accessible and economical.

Target Audience

The primary target audience includes researchers and diagnostic companies requiring high-quality recombinant proteins for research, assay development, and diagnostic kit manufacturing.

Features

  • PtX™ Technology: A plant-based transient expression platform using Nicotiana benthamiana plants as mini-bioreactors.
  • Scalable protein production: Enables rapid and flexible scaling to meet varying demands.
  • Animal-free production: Eliminates the use of animals or animal products, ensuring an ethical source of proteins.
  • Recombinant antibodies and antigens: Production of proteins for research and diagnostic applications.
This profile is AI-generated and may contain inaccuracies.